Muse Cell Therapy for Neuronal Repair in Vascular Dementia

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There are no effective treatments for vascular dementia, and existing therapies for cerebrovascular disorders do not address the underlying issue of oxygen and nutrient supply to brain neurons, necessitating a safe and definitive cure.

Innovation Solution

Administration of SSEA-3-positive pluripotent stem cells, known as Muse cells, which are derived from mesenchymal tissues, to protect neurons and enhance cognitive function in vascular dementia models, allowing them to migrate, engraft, and differentiate at impaired brain sites without requiring induction.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional drugs (brain blood flow improving drugs, brain blood vessel dilators, cerebral metabolic activators) are used for treatment, then cerebrovascular disorders and cerebral infarction can be treated, but vascular dementia cannot be fundamentally treated

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidapplicability to vascular dementia

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent introduces a novel intermediary substance (specific compound or cell type) that acts as a bridge between conventional treatments and vascular dementia pathology. This intermediary mechanism enables the treatment to specifically address vascular dementia by mediating the interaction between blood flow improvement and neuronal protection, thereby resolving the contradiction between treating cerebrovascular disorders and effectively treating vascular dementia

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes key parameters of the treatment approach by identifying specific molecular targets, cell types, or biochemical pathways that are uniquely relevant to vascular dementia. By adjusting these parameters (e.g., specificity to vascular dementia pathology, mechanism of action), the treatment transitions from general cerebrovascular support to targeted vascular dementia therapy

Inventive Principle:

Principle #35Parameter changes

2Strength

If bone marrow stem cells are transplanted for regenerative therapy, then tissue regeneration can be promoted, but complete cure of vascular dementia has not been achieved

Engineering Contradiction:

Improvetissue regeneration capabilityVSAvoidcurative effectiveness

Core Design Contradiction:

StrengthVSReliability

Solution Approach 1:

The patent extracts and utilizes specific properties or components from bone marrow stem cells (such as paracrine factors, exosomes, or specific cell subsets) that are responsible for the therapeutic effect. By isolating and applying these extracted elements, the treatment achieves more reliable and complete curative effects while maintaining the regenerative benefits

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent employs a composite therapeutic approach that combines multiple elements (e.g., stem cells with specific growth factors, or multiple cell types in combination) to create a synergistic treatment. This composite strategy enhances both tissue regeneration and curative effectiveness by addressing multiple pathological aspects of vascular dementia simultaneously

Inventive Principle:

Principle #40Composite materials

Data Source

PatentUS12599631B2Agent for treating or preventing vascular dementia

Publication Date: 2026.04.14 TOHOKU UNIV

AI summary

An object is to provide a cell product for treating and/or preventing vascular dementia. The present invention provides a cell product for treating or preventing vascular dementia, containing a SSEA-3-positive pluripotent stem cell (Muse cell) derived from a mesenchymal tissue in a living body or a SSEA-3-positive pluripotent stem cell derived from a cultured mesenchymal cell.